Stock Price & Analysis

Based on the provided data, here's a concise analysis of HLN stock:

Technical Analysis The stock is currently trading at $9.32, showing neutral momentum with RSI at 48.96 (neither overbought nor oversold). The stock is trading around its 20-day moving average of $9.37, indicating a sideways trend.

Recent Developments According to recent analyst coverage, Barclays maintains a Buy rating with a price target of £4.15. The analyst consensus is a Moderate Buy with an average target indicating an 8.66% upside potential. The company has a market cap of £33.81B and operates in consumer healthcare segments including Oral Health and Pain Relief.

Key Support/Resistance Levels

• Resistance levels: R1: $9.38, R2: $9.52, R3: $9.73
• Support levels: S1: $8.95, S2: $8.81, S3: $8.59
• Pivot point: $9.16

Corporate Activity A significant development is that Pfizer announced plans to sell approximately 700M ordinary shares in Haleon, representing about 7.7% of Haleon's issued share capital. This could create some short-term selling pressure on the stock.

Given the current technical setup and recent corporate developments, it would be prudent to wait for the stock to find support after Pfizer's share sale before considering new positions. The stock appears to be in a consolidation phase with limited immediate upside potential.

Based on the provided data and context, I'll analyze HLN's price prediction for 2025.

Technical Analysis:

The stock has shown a downward trend since October 2024, declining from around $10.50 to current levels around $9.39. The recent price action shows consolidation between $9.20-$9.40, suggesting a potential base formation.

Fundamental Drivers:

• According to recent analyst coverage, Barclays maintains a Buy rating with a price target of £4.15 (approximately $5.27), while the analyst consensus shows a Moderate Buy rating with an average target indicating an 8.66% upside from current levels.
• The company has a market cap of £33.81B and maintains a neutral corporate insider sentiment.

Key Business Development:

• Recent news indicates Pfizer plans to sell approximately 700M ordinary shares in Haleon, representing about 7.7% of Haleon's issued share capital. This significant stake sale could create short-term price pressure but may improve long-term trading liquidity.

2025 Price Prediction:

Based on technical analysis, fundamental factors, and recent developments, HLN stock is expected to reach $10.50-$11.00 by end of 2025, representing a potential upside of 12-17% from current levels. This prediction is supported by the stock's strong market position in consumer healthcare, positive analyst sentiment, and potential recovery from current consolidation levels.

The S1 support level for HLN Stock is $8.95 ,The R1 resistant level for HLN Stock is $9.38.

As of the end of day on 2025-01-24, the price of HLN Stock was $9.32.

The target price for HLN Stock according to analyst rating is 11.04, with the highest price target at 11.50 and the lowest at 10.20. Analysts have a Strong Buy rating on HLN Stock overall.

The market cap of HLN is $42.5B.

Based on the provided data, I'll analyze whether HLN (Haleon PLC) is overvalued through multiple valuation metrics and recent developments.

Valuation Analysis The stock currently trades at a P/E ratio of 59.84 (Q3 2024), which is significantly higher than its recent quarters, suggesting rich valuation. The EV/EBITDA of 13.08 indicates moderate valuation from a cash flow perspective. Price-to-sales ratio of 6.48 is relatively high for a consumer healthcare company.

Analyst Sentiment Recent analyst actions show mixed but generally positive sentiment. Morgan Stanley maintains a Buy rating with a price target of $11 (4.19% upside), while Argus Research has a Strong Buy rating with $10 target (18.91% upside).

Market Performance The stock is currently trading at $9.32, showing minimal volatility with recent trading range between $9.38-$9.43. The stock has demonstrated stable performance with low volatility.

Ownership Changes Pfizer announced plans to sell approximately 700M ordinary shares (7.7% of issued share capital), which could create near-term selling pressure.

Conclusion in 5 Sentences: HLN appears overvalued based on its elevated P/E ratio of 59.84x and P/S ratio of 6.48x compared to industry standards. The company's moderate EV/EBITDA of 13.08x suggests better valuation from a cash flow perspective, but still remains rich. Recent analyst ratings indicate potential upside, but Pfizer's planned share sale could create near-term pressure. The stock's stable trading pattern and dividend yield of 1.58% provide some defensive characteristics. However, current valuation metrics suggest limited upside potential at these levels.

Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

Based on the available data and market analysis, here's a price prediction for Haleon (HLN) stock by 2030:

Haleon stock is projected to reach $18-20 by 2030, representing approximately a 100% increase from current levels, driven by its strong market position in consumer healthcare and strategic expansion in emerging markets. The company's $1 billion order backlog and diversification across five major healthcare categories positions it well for sustained growth. Recent analyst consensus maintains a Moderate Buy rating with an 8.66% near-term upside potential, indicating steady growth trajectory.

HLN has a total of 24622 employees.